Colorectal cancer recurrence gene expression signature
AssigneesH. Lee Moffitt Cancer Center and Research Institute, Inc., Gibbs Cancer Center & Research Institute
InventorsMichael Schell, Timothy Yeatman
Life of this patent
Estimating the term…
Abstract
Disclosed are gene signatures that may be used to predict the recurrence of colorectal cancer in a human patient. These signatures can be used to determine when to treat a patient with post-operative adjuvant chemotherapy, i.e., when a high risk of colorectal cancer recurrence is predicted.
Claims20
A method for predicting the recurrence of colorectal cancer in a human patient, comprising:
- (a) assaying colorectal cells obtained from the human patient for the expression level of ten (10) or more genes listed in TABLE 2A, or their corresponding expression products, and ten (10) or more genes listed in TABLE 2B, or their corresponding expression products, and using normalized values of the expression levels to calculate a colorectal cancer (CRC) score;
- (b) assaying colorectal cells obtained from the human patient for the expression levels of ten (10) or more genes listed in TABLE 1A, or their corresponding expression products, and ten (10) or more genes listed TABLE 1B, or their corresponding expression products, and using normalized values of the expression levels to calculate an Epithelial to Mesenchymal Transition (EMT) score;
- and
- (c) calculating the difference between the CRC score and the EMT score to arrive at a Recurrence Signature Score that predicts risk of colorectal cancer recurrence.
A method for analyzing a colorectal cancer tissue sample to determine adjuvant chemotherapy is needed to prevent colorectal cancer recurrence in a human patient, the method comprising:
- (a) assaying colorectal cells obtained from the human patient for normalized expression values of ten (10) or more genes listed in TABLE 1A, ten (10) or more genes listed in TABLE 1B, ten (10) or more genes listed in TABLE 2A, and ten (10) or more genes listed in TABLE 2B;
- and
- (b) inputting the normalized expression values into a computer programmed to execute an algorithm to convert the normalized expression values to a Recurrence Signature Score indicative of a likelihood of the risk of colorectal cancer recurrence, wherein the algorithm gives reduced weight to the normalized expression values for genes that are listed in more than one of TABLE 1A, TABLE 1B, TABLE 1C, and TABLE 1D.
Dependencies are inferred from the claim text.